RARE shares jump 13% after-hours following FDA approval
Ultragenyx Pharmaceutical’s RARE stock extended after-hours gains after U.S. regulators approved Fayuvi, the first treatment for Sanfilippo syndrome type A.
Ultragenyx Pharmaceutical Inc. (RARE) shares continued to climb after the close on Thursday after U.S. regulators approved Fayuvi, the first treatment for Sanfilippo syndrome type A. The move came after a sharp selloff.
A day earlier, the stock had hit a new 52-week low of $12.73, and it…